Erasca (ERAS) Profit After Tax (2020 - 2026)
Erasca (ERAS) reported Profit After Tax of -$183.4 million for Q1 2026, down 492.39% on a YoY basis from $46.7 million in Q1 2025, and down 530.55% quarter-over-quarter from -$29.1 million in Q4 2025.
Erasca (ERAS) Profit After Tax (2020 - 2026) Analysis & Trends
Erasca has reported Profit After Tax for 7 years, with the latest figure at -$183.4 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 492.39% year-over-year to -$183.4 million; the trailing twelve-month figure through Mar 2026 stood at -$277.0 million (down 75.78% YoY), and the FY2025 full-year result was -$124.5 million, up 22.95% from the prior year.
- Profit After Tax for Q1 2026 stood at -$183.4 million, down from -$29.1 million in the prior quarter.
- The five-year high for Profit After Tax was -$29.1 million in Q4 2025, with the low at -$183.4 million in Q1 2026.
- Historically, Profit After Tax has averaged -$49.3 million across 5 years, with a median of -$33.2 million in 2023.
- Annual changes were most pronounced in 2023 — Profit After Tax jumped 78.04% — and 2026, when it slumped 492.39%.
- Erasca's Profit After Tax stood at -$135.2 million in 2022, then jumped by 78.04% to -$29.7 million in 2023, then declined by 8.52% to -$32.2 million in 2024, then climbed by 9.74% to -$29.1 million in 2025, then slumped by 530.55% to -$183.4 million in 2026.
- The last three Profit After Tax figures came in at -$183.4 million (Q1 2026), -$29.1 million (Q4 2025), and -$30.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -183.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -183.44 Mn |
| Dec 31, 2025 | -29.09 Mn |
| Sep 30, 2025 | -30.61 Mn |
| Jun 30, 2025 | -33.88 Mn |
| Mar 31, 2025 | -30.97 Mn |
| Dec 31, 2024 | -32.23 Mn |
| Sep 30, 2024 | -31.20 Mn |
| Jun 30, 2024 | -63.20 Mn |
| Mar 31, 2024 | -35.02 Mn |
| Dec 31, 2023 | -29.70 Mn |
| Sep 30, 2023 | -30.36 Mn |
| Jun 30, 2023 | -31.78 Mn |
| Mar 31, 2023 | -33.20 Mn |
| Dec 31, 2022 | -135.25 Mn |
| Sep 30, 2022 | -35.49 Mn |
| Jun 30, 2022 | -35.61 Mn |
| Mar 31, 2022 | -36.46 Mn |
| Dec 31, 2021 | -30.46 Mn |
| Sep 30, 2021 | -46.07 Mn |
| Jun 30, 2021 | -28.21 Mn |